Brief: Quantum Genomics Announces Positive Results From New Preclinical Studies On Firibastat

Quantum Genomics SA

20/03/2019 17:06

March 20 (Reuters) - QUANTUM GENOMICS SA  ALQGC.PA :
    * QUANTUM GENOMICS ANNOUNCES POSITIVE RESULTS FROM NEW
PRECLINICAL
STUDIES ON FIRIBASTAT
    * RESULTS CONFIRMED THAT FIRIBASTAT DID NOT INDUCE TOXICITY
TO
MALE AND FEMALE REPRODUCTIVE FUNCTIONS, GESTATION, EMBRYONIC AND
FETAL DEVELOPMENT, AND FARROWING
    * EXCELLENT RESULTS OF THIS PRECLINICAL STUDY FURTHER PROVE
SAFETY
OF FIRIBASTAT ADMINISTRATION, BRINGING US CLOSER TO LAUNCH OF
OUR UPCOMING PHASE 3 CLINICAL TRIAL FOR RESISTANT HYPERTENSION
THAT WE HOPE TO LAUNCH IN SECOND HALF OF 2019
    * ANIMAL MODELS IN THE STUDY WERE EXPOSED TO QUANTITIES OF
PRODUCT
SIGNIFICANTLY HIGHER THAN THOSE TESTED IN PATIENTS, PARTICULARLY
HYPERTENSIVE PATIENTS ENROLLED IN PHASE IIB NEW-HOPE STUDY

Source text for Eikon:  ID:nGNX2Pfhrw 
Further company coverage:  ALQGC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))